The incidence of cardiovascular disease is higher in HIVpositive (HIV + ) patients than it is in the average population, and combination antiretroviral therapy (cART) is a recognized risk factor for cardiovascular disease. However, the molecular mechanisms that link cART and cardiovascular disease are currently unknown. Our study explores the role of the activation of p90RSK, a reactive oxygen species-sensitive kinase, in engendering senescent phenotype in macrophages and accelerating atherogenesis in patients undergoing cART.
R
emarkable progress in the treatment of HIV infection has dramatically changed the outlook of this disease from one with no treatment to that of a chronic, manageable disease, at least in developed countries. 1 Although there has been a steady increase in longevity, the lifespan of patients still falls short of that of the average population because of the premature development of non-AIDS comorbidities such as cardiovascular disease (CVD) and metabolic syndrome. 2, 3 In addition to the traditional risk factors associated with CVD, 4 both HIV infection and antiretroviral drugs have been proposed to be risk factors. 5 However, the mechanisms underlying this risk remain unclear.
A potential target of both HIV viral products and antiretroviral drugs is myeloid cells, which are important effectors in atherogenesis. In particular, the use of antiretroviral therapy (cART) has been recently associated, directly and indirectly, with premature senescence and subsequent CVD. [6] [7] [8] It has been suggested that the following 4 components of the senescent phenotype would be the key to evoke CVD: (1) telomere shortening-mediated DNA damage and subsequent p16 and p21 induction, (2) reactive oxygen species (ROS) induction, (3) inflammation, and (4) impairment of efferocytosis. [9] [10] [11] However, how these 4 events are simultaneously provoked by cART remains largely unknown.
In this study, we expanded on our previous work on CVD that implicated p90RSK, 12 a unique serine/threonine kinase with 2 distinct functional kinase domains, 13 as a key molecule in atherogenesis. p90RSK is a redoxsensitive kinase, and p90RSK-mediated ERK5-S496 phosphorylation is important for endothelial activation (ie, inflammation) and dysfunction by inhibiting ERK5 and the transcriptional activity of an anti-inflammatory transcriptional factor, Krüppel-like Factor 2.
14 However, p90RSK may also play a role in efferocytosis, as suggested by the results of our recent study in which macrophage-specific ERK5 activity was found to be increased when these cells were allowed to feed on apoptotic cells or were treated by statins. 15 Under these conditions, macrophages also enhanced phagocytic activity by upregulating the expression of efferocytosisrelated molecules. In addition, depletion of ERK5 in macrophages increased the expression of inflammationrelated genes and atherosclerotic plaque formation and reduced the thickness of the fibrotic cap of advanced plaques. Because p90RSK activation inhibits ERK5 transcriptional activity in endothelial cells, 14 we hypothesize that macrophage p90RSK activation downregulates inflammation as well as macrophage efferocytosis.
Several chemical compounds and drugs are known to directly and indirectly cause mitochondrial oxidative stress and dysfunction and to subsequently induce CVD. 16 Of note, it has been reported that ≈10% of drugs in the last 4 decades have been recalled from the clinical market worldwide because of cardiovascular safety concerns, and accumulating evidence points to mitochondrial dysfunction as the causative factor. 16 cART can induce mitochondrial oxidative stress, and this outcome may be related to the increased incidence of CVD in patients with AIDS. 16, 17 To this end, we determined how p90RSK in monocytes/macrophages plays a major role in mediating the cART-induced atherogenesis that frequently occurs in HIV-positive (HIV + ) patients. Our studies suggest that the cART regimen activates monocyte/macrophage p90RSK, thereby regulating the genes that are involved in efferocytosis and inflammation. It is important to note that peripheral monocytes isolated from cART-treated HIV + patients exhibited enhanced sensitivity to oxidative stress compared with those from HIV-negative (HIV -) controls. This height-
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What Is New?
• p90RSK activation in monocyte/macrophage contributes to the recognized association between combination antiretroviral therapy and cardiovascular disease.
• Combination antiretroviral therapy initiates a cycle of p90RSK activation/sensitization via increasing the production of mitochondrial reactive oxygen species in monocytes/macrophages. • p90RSK activation inhibits nuclear factor erythroid 2-related factor 2 (NRF2)-antioxidant response element transcriptional activity, which is known to accelerate the aging process.
• p90RSK-NRF2 signaling pathway sensitizes monocytes/macrophages to reactive oxygen species and accelerates atherosclerosis by simultaneously inducing these 4 components of the senescent phenotype: telomere shortening and subsequent p16 and p21 induction, reactive oxygen species induction, inflammation, and impairment of efferocytosis.
What Are the Clinical Implications?
• Inhibition of p90RSK activity can be a viable approach to controlling atherosclerosis and reducing cardiovascular disease in HIV-positive patients.
• In vitro drug screening using p90RSK activation by incubating monocyte/macrophage could help screening for potential proatherogenic drugs but could also be used to evaluate drugs that could prevent atherogenesis. • H 2 O 2 -induced p90RSK activation in CD14 + monocytes obtained from patients may serve as a viable biomarker to predict future cardiovascular disease events in HIV-positive patients.
• Novel therapeutic approach aimed at reducing p90RSK activity should be investigated for preventing future cardiovascular disease events. ORIGINAL RESEARCH ARTICLE ened sensitivity was triggered by a reduction in nuclear factor erythroid 2-related factor 2 (NRF2)-antioxidant response element (ARE) transcriptional activity, which is known to accelerate the aging process. 18, 19 In fact, we found that NRF2 activation abolished the induction of the senescent phenotype. Because p90RSK activation in myeloid cells appears to play a crucial role in atherosclerotic plaque formation, we posit that p90RSK activation in peripheral monocytes serves as a viable biomarker and target for the treatment of CVD, especially in individuals undergoing cART for HIV.
METHODS
Additional details of the experimental procedures are included in the online-only Data Supplement information. The data, analytic methods, and study materials that support the findings of this study are available from the corresponding authors on reasonable request.
Population Studies
The study was approved by the Institutional Review Board of the University of Rochester, and subjects gave informed consent.
Statistical Analysis (Clinical Study)
The descriptive characteristics are summarized in Table I in the online-only Data Supplement. Percentages and frequencies are reported for discrete variables, and means and SDs are reported for continuous characteristics. Fisher exact test was used to compare the proportion of categorical variables such as sex and race between the HIV + and control groups. Welch t test was used to compare the mean values of continuous variables such as age and the Reynolds risk score between the HIV + and control groups. For multigroup comparisons, we performed 1-way ANOVA followed by Bonferroni post hoc testing. When groups exhibited unequal variances, Welch ANOVA was used to perform multigroup comparisons. All analyses were performed using R 3.3.0 (R Foundation for Statistical Computing), SAS 9.3 (SAS Institute), and Prism 5.0 (GraphPad Software) software.
RESULTS

Various cART Components Activate p90RSK in Monocytes and Macrophages
First, we determined whether the commonly used cART drugs activate p90RSK in vitro in human peripheral blood monocytes as well as bone marrow-derived macrophages (BMDMs) obtained from C57BL/6 mice. These cells were used to measure both p90RSK phosphorylation as well as phosphorylation of its downstream targets, ERK5, at the S496 residue (important for inhibiting ERK5 transcriptional activity) 14 and at the threonine-glutamic acid-tyrosine residue (TEY) motif (important for ERK5 kinase activity). 20 We found that efavirenz (non-nucleoside reverse transcriptase inhib- Figure IA , IC, IJ, and I1K in the online-only Data Supplement) also produced equivalent changes in p90RSK activation in dose-and timedependent manners.
Integrase inhibitors constitute an important element of the cART regimen, and it is noteworthy that increasing doses of elvitegravir resulted in the upregulation of p90RSK activity within the indicated time points ( Figure IK and IL in the online-only Data Supplement), whereas raltegravir failed to exert such an effect on p90RSK ( Figure IJ in the online-only Data Supplement). As we described in the Methods, each drug concentration used in this study was within the therapeutic range of plasma concentration in humans. Taken together, our findings suggest that a large number of cART regimens, either alone or in combination, are capable of activating p90RSK in monocytes and macrophages. Given these results, we used TDF/FTC/ATV/RTV in subsequent experiments unless specified otherwise.
p90RSK in Peripheral Monocytes Is Primed for Activation by cART in HIV +
Individuals
Next, we determined whether p90RSK activation is also affected by cART in HIV + patients. As shown in Table I in the online-only Data Supplemented, we enrolled 2 cohorts in this study: (1) 104 HIV + patients ≥45 years of age with viral load ≤200 copies/mL (1 on NRTIs, 23 on NNRTIs, 56 on multicategory [eg, NNRTI and integrase inhibitors], and 24 on integrase inhibitor-based cART regimens) on stable cART for ≥1 year; and (2) 92 HIV − controls matched for similar cardiovascular risk factors using the Reynolds cardiovascular risk score. 21 Blood was collected at the time of enrollment from all subjects, and a subset of it (HIV + : n=92; HIV − : n=86) was used to measure the levels of total and phosphorylated p90RSK in peripheral CD14 + monocytes by flow cytometry.
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Because p90RSK is a redox-sensitive kinase, 22 the sensitivity of monocytes to ROS as a known inducer of p90RSK activation was also assessed by the ex vivo treatment of monocytes with H 2 O 2 (200 µmol/L) for 4 minutes. Although the basal levels of phospho-p90RSK remained comparable in all subjects, regardless of their HIV status (P=0.544; Figure 1C ), HIV + patients receiving cART displayed a sharp increase in the sensitivity of monocytic p90RSK to the exposure of H 2 O 2 (Welch 2-sample t tests, P<0.0001; Figure 1D ), suggesting a + peripheral blood monocytes from HIV + and HIV − patients. p90RSK activity was determined using the ratio between phosphorylated p90RSK and total p90RSK, detected by flow cytometry, as described in the Methods. The p90RSK activity after H 2 O 2 stimulation was significantly higher (P=0.0000363) in the HIV + group. No significant difference was detected in basal p90RSK activity. E and F, The basal levels (E) and levels after H 2 O 2 stimulation (F) of p90RSK activity in monocytes from HIV + patients undergoing treatment with integrase inhibitors, multiple combination treatments, and NNRTI regimens, as described in the Methods. No significant difference was found among these 3 groups. G and H, The basal levels (G) and levels after H 2 O 2 stimulation (H) of p90RSK activity by viral load detectable status in the HIV + group, as described in the Methods. Yes, n=11; no, n=74. The p90RSK activity in both basal (P=0.0012245) and H 2 O 2 -stimulated (P=0.0022490) samples was significantly higher in the no virus detectable group than those in the virus detectable group. DMSO indicates dimethyl sulfoxide; EFV, Efavirenz; ERK5, extracellular signal regulated kinase 5; H 2 O 2 , Hydrogen Peroxide; Inhib, integrase inhibitors; Multi-C, multiple combination treatments; NNRTI, non-nucleoside reverse transcriptase inhibitor; P90RSK, p90 ribosomal s6 kinase; and TEY, Thr-Glu-Tyr motif. Figure 1E and 1F and Table II in the online-only Data Supplement). These results suggest that the increased sensitivity of monocyte p90RSK in response to H 2 O 2 was not because of a specific drug in the cART regimen. We also compared the p90RSK sensitivity of monocytes of HIV + patients with detectable (n=11) and undetectable (n=74) baseline HIV viral loads by Welch t test. We found that both basal and H 2 O 2 -treated p90RSK activation levels overlapped between those with detectable and undetectable viremia despite the mean being significantly higher in those with undetectable virus ( Figure 1G and 1H). This outcome is likely a spurious effect of the large sample difference between the 2 groups. Overall, these data suggest that the p90RSK activation detected in our HIV + patients was not dependent on the high level of HIV replication. Furthermore, the CD4 counts were not significantly associated with both basal and H 2 O 2 -treated p90RSK activation levels ( Figure 2A and 2B in the online-only Data Supplement).
Circulation
Next, we assessed whether elevated sensitivity of monocyte-p90RSK to oxidative stress in HIV + individuals was also associated with plaque formation in carotid vessels. To this end, carotid vascular sonography was performed in study participants; the results showed that 28.3±4.7% and 35.6±4.7% (mean±SEM) of HIV + and HIV − individuals, respectively, exhibited plaques in both carotids. A univariate logistic regression analysis did not reveal any significant difference in plaque formation in both sides of the carotid arteries between these 2 groups (Table III in the online-only Data Supplement). A multivariate logistic regression analysis was performed on HIV status, Reynolds score, and basal or H 2 O 2 -induced p90RSK activation. Although neither HIV status nor basal p90RSK activation was significantly associated with plaque formation, their interaction was associated with a significant increase in the risk of forming plaques on both carotid arteries (P=0.0464; Table IV in the online-only Data Supplement). These results suggest that subjects with both HIV and high basal p90RSK activity in peripheral monocytes are at a significantly higher risk of plaque formation. Last, we studied the relationship between the Reynolds score and p90RSK activation and found no significant correlation with the Reynolds score ( Figure 2C and 2D in the online-only Data Supplement), suggesting that the activation of p90RSK in human monocytes is independent of conventional CVD risk factors.
cART Primes Monocytes and Macrophages to Oxidative Stress by Decreasing Antioxidant Expression and Driving Senescence
As shown in Figure 1D , we found that cART appears to prime human monocytes in response to H 2 O 2 . To confirm this observation in more amenable cell systems, we isolated bone marrow cells from C57BL/6 mice and cultured them to obtain macrophages. These mouse BMDMs were first treated with cART for 16 hours and then with H 2 O 2 (200 µmol/L) for ≤30 minutes, and p90RSK activation was determined. We found that cART pretreatment significantly increased p90RSK phosphorylation (Figure 2A and 2B).
To gain insight into the mechanism of this priming effect, we tested the following 2 potential mechanisms:
(1) decreased expression of antioxidants, and (2) telomere shortening, both of which are known senescent phenotypes, as we discussed in the Introduction. We previously reported that ERK5 transcriptional activity, but not kinase activity, is inhibited by p90RSK activation, which induces ERK5 S496 phosphorylation in endothelial cells.
14 Others have shown that ERK5 can upregulate the activity of NRF2, which is a transcription factor that is well known to regulate antioxidant expression. 23 ,24 Therefore, we hypothesized that p90RSK activation, induced by cART, inhibits NRF2 activity and antioxidant expression via ERK5 S496 phosphorylation.
To test this hypothesis, we first determined whether p90RSK activation by cART inhibits ERK5 transcriptional activity. We co-overexpressed p90RSK and a constitutively active form of MEK5 in BMDMs and found that constitutively active form of MEK5-induced ERK5 transactivation was indeed significantly inhibited by p90RSK overexpression ( Figure IIIA in the online-only Data Supplement). However, because MEK5 also phosphorylates the ERK5 TEY motif, which can activate both the kinase and transcriptional activities of ERK5, we determined whether cART-activated p90RSK phosphorylates both or just 1 site. As expected, cART increased p90RSK phosphorylation, but, more importantly, we found that only ERK5 S496 was phosphorylated ( Figures 1A, 1B , 2A, and 2B and Figure I in the online-only Data Supplement). These results are consistent with the human data shown in Figure 1A and 1B that the effects of efavirenz and the combination of TDF/FTC/ATV/RTV and TDF/FTC/MVC on p90RSK activation were completely inhibited by a p90RSK-specific inhibitor, FMK-MEA. We also confirmed that 16 hours of cART pretreatment of BMDMs significantly enhanced H 2 O 2 -induced p90RSK activation and ERK5 S496 but not TEY motif phosphorylation ( Figure 2A and 2B).
We next tested cART's effects on ERK5 transcriptional activity in RAW264.7 cells. In line with the observations described earlier, we found that treatment
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with efavirenz alone or exposure to the combination of TDF/FTC/ATV/RTV significantly inhibited ERK5 transcriptional activity, which was reversed by pretreatment with FMK-MEA ( Figure IIIB and IIIC in the online-only Data Supplement). Consistently, such a reduction in ERK5 transcriptional activity by cART was found to be completely abolished in BMDMs that overexpressed ERK5-S496A mutant (ERK5 S496A) 14 but not WT ERK5 (ERK5-WT; Figure IIID in the online-only Data Supplement).
We investigated how p90RSK is involved in antioxidant expression. As shown in Figure 2C and Figure IVA ), and then treated with vehicle or cART for 18 h. Telomere lengths were determined by measuring the fluorescent telomeric signal intensity of the fluorescein-conjugated PNA probe, as described in the Methods. Results are represented as the relative telomere length (%; mean±SD). The telomere length of human T-cell leukemia cell line (1301) cells was set to 100%. **P<0.01. ERK5 indicates extracellular signal regulated kinase 5; Gas6, Growth arrest specific 6; GPx1, Glutathione peroxidase 1; H 2 O 2 , Hydrogen Peroxide; HO1, Heme oxygenase 1; Min, minutes; NRF2-ARE, MF-E2 related factor 2-antioxidant responsive element; P90RSK, p90 ribosomal s6 kinase; PNA, peptide nucleic acid probe; TEY, Thr-Glu-Tyr motif; and Trx1, Thioredoxin 1. ORIGINAL RESEARCH ARTICLE cART significantly decreased the expression of the antioxidant molecules such as thioredoxin 1, heme oxygenase 1, catalase, and glutathione peroxidase 1. However, this decrease was completely reversed by pretreatment with FMK-MEA. Because NRF2 regulates the expression of antioxidant proteins, we determined whether cARTinduced p90RSK activation negatively regulated NRF2. Although cART did not affect NRF2 expression (including both 60 and 110 kDa isoforms; Figure 2C and Figure To determine the role of NRF2 in cART-induced reduction of antioxidant molecule expression and telomere length, we used a cell-penetrating, NRF2-KEAP1-binding inhibitory peptide, CAS 1362661 (NRF2A), that can specifically activate NRF2 transcriptional activity. 25 As shown in Figure 2D (right), the reduction in NRF2-ARE transcriptional activity was completely prevented in BMDMs by pretreatment with NRF2A. It is well known that senescent cells show proinflammatory and prooxidative phenotypes. 26 The G-rich sequence of telomere forms quadruplex structures in which oxidized equivalents can be trapped. This structural characteristic of telomere protects chromosomes from oxidative damage. 27 We found that cART significantly decreased telomere lengths by activating p90RSK and inhibiting NRF2-ARE activity ( Figure 2E ).
We previously reported that macrophage efferocytosis and the expression of the inflammatory phenotype are controlled by ERK5 15 ; however, the role of the macrophages p90RSK and NRF2 in efferocytosis and inflammation remains unclear. Therefore, we determined whether the activation of p90RSK and NRF2 by cART plays a role in the expression of Gas6 (an efferocytosisrelated molecule) and TNFα (an inflammation-related molecule). As shown in Figure 2C and Figure IVD in the online-only Data Supplement, Gas6 expression was inhibited whereas TNFα expression was increased in a p90RSK-dependent manner. We also confirmed that pretreatment with cART, followed by H 2 O 2 stimulation, inhibited the expression of the antioxidant proteins thioredoxin 1 heme oxygenase 1, catalase, and glutathione peroxidase 1 and enhanced p90RSK activation and ERK5 S496 phosphorylation ( Figure 3A and Figure  VA in the online-only Data Supplement). All of these events were profoundly diminished by NRF2A treatment.
cART was found to increase the expression of cell senescence markers (p16 and p21); this increase was inhibited by FMK-MEA ( Figure 2C and Figure IVC in the online-only Data Supplement) and NRF2A ( Figure 3A and Figure VB in the online-only Data Supplement), suggesting that cART-induced p90RSK activation and subsequent regulation of NRF2-ARE play a role in telomere dysfunction and an accelerated senescence of macrophages. Taken together, these data suggest that cART increases the sensitivity of monocytes/macrophages to oxidative stress by both downregulating NRF2 transcriptional activity and accelerating the process of premature aging. Although the role of NRF2 in upregulating CD36 expression has been implicated in atherosclerotic plaque formation, 28 such changes in CD36 levels after cART treatment were not detected in our study (Figures 2C and 3A and Figures IVB and VC in the onlineonly Data Supplement). Last, we found that cART decreased Gas6 expression and induced TNFα expression, both of which were inhibited by FMK-MEA ( Figure 2C and Figure IVD in the online-only Data Supplement) and NRF2A ( Figure 3A and Figure VD in the online-only Data Supplement). These results suggest that p90RSK activity and NRF2-ARE transactivation contribute to regulating ERK5-mediated efferocytosis and inflammation-related events. Taken together, our study indicates the crucial role of p90RSK-NRF2 signaling in coordinately regulating 4 components of the senescent phenotype: (1) telomere shortening-mediated DNA damage and subsequent p16 and p21 induction, (2) ROS induction, (3) inflammation, and (4) impairment of efferocytosis induced by cART.
Because our study showed that p90RSK is a redoxsensitive kinase, 22 we investigated the effects of a mitochondrial ROS-targeted antioxidant, MitoTEMPO, on p90RSK activation by cART reagents. MitoTEMPO inhibited the phosphorylation of p90RSK and ERK5 S496 by TNFα (positive control) and cART reagents, except RPV (NNRTI; Figure 3B and 3C). We also measured both intracellular and mitochondrial ROS by using CM-H 2 DCF-DA and MitoSOX red, respectively. Various cART drugs and TNFα, which upregulated p90RSK activity, increased both intracellular and mitochondrial ROS, and MitoTEMPO significantly inhibited both mitochondrial and intracellular ROS levels ( Figure 3D and 3E) . These results are consistent with the crucial role of mitochondrial ROS production, induced by most cART regimens, in activating p90RSK and reducing ERK5 transcriptional activity, suggesting that cART targets mitochondria.
Increased p90RSK Activity During cARTInduced Inflammation and Efferocytosis
To further study the role of p90RSK in myeloid cell inflammation and efferocytosis, we used transgenic mice expressing the dominant-negative (ie, kinase-dead) form of p90RSK (DN-p90RSK) specifically in myeloid cells (DN-p90rsk-MTg). BMDMs were derived from the DN-p90rsk-MTg and corresponding nontransgenic littermate control (NLC) mice. In cells from NLC, but not DN-p90rsk-MTg, mice, cART increased the expression of proinflammatory genes (TNFα and iNos) and decreased the expression level of efferocytosis-related genes (Gas6, Anxa1, and Tyro3), both in a p90RSK activation-depen- Our sonography studies revealed that plaque formation in carotid arteries was correlated with HIV infection (ie, cART treatment) and increased p90RSK activity. To more closely examine the effect of cART on atherosclerosis, we used the partial carotid artery ligation (PCL) model, Figure 2C . They were then incubated with H 2 O 2 (200 µmol/L) for 10 minutes. Western blotting analysis was performed using specific antibodies against the proteins indicated on the right. Representative images from 3 independent experiments are shown. B and C, Various cART drugs increased p90RSK activity, ERK5 S496 phosphorylation, and ERK5 TEY motif phosphorylation via mitochondrial reactive oxygen species (ROS) production. BMDMs from C57BL/6 mice were treated with MitoTEMPO (20 µmol/L) for 1 h and incubated with various cART drugs, as indicated, for 10 min. Western blotting analysis was performed using specific antibodies against the proteins indicated in the figure. C, The graph represents densitometry data of immunoblots from 3 independent experiments (n=3) in B, mean±SD. **P<0.01. D and E, BMDMs from C57BL/6 mice were incubated with various cART drugs and TNFα with vehicle or MitoTEMPO, as indicated. MitoSox Red (D) and H 2 DCF-DA (E) were added, and mitochondrial ROS (D) and intracellular ROS (E) levels were detected as described in the Methods. Mean±SD (n=3). **P<0.01. ATV indicates Atazanavir; ERK5, extracellular signal regulated kinase 5; EVG, Elvitergravir; FTC, Emtricitabine; Gas6, Growth arrest specific 6; GPx1, Glutathione peroxidase 1; H 2 DCFDA, 2',7'-dichlorodihydrofluorescein diacetate; H 2 O 2 , Hydrogen Peroxide; HO1, Heme oxygenase 1; MVC, Maraviroc; NNRTI, nonnucleoside reverse transcriptase inhibitor; P90RSK, p90 ribosomal s6 kinase; RGV, Raltegravir; RPV, Rilpivirine; RTV, Ritonavir; TDF, Tenofovir; TEY, Thr-Glu-Tyr motif; TNF, Tumor necrosis factor; and Trx1, Thioredoxin 1. 
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which experimentally creates an area of disturbed flow where atherogenic responses are induced in a short period of time. 29 PCL surgery was performed on Ldlr −/− mice on a high-fat diet and treated with cART or vehicle for 2 weeks. Three weeks after PCL, mice were euthanized and plaque formation in the left and right carotids evaluated by measuring the gross lesion (%) and the plaque area using histological sections as described in the Methods. cART treatment accelerated plaque formation compared with vehicle treatment (Figure 4G through 4I) . We did not find any difference in body weight or cholesterol level between cART-and vehicle-treated mice ( Figure VIA and VIB in the online-only Data Supplement).
Next, we examined whether cART treatment affects the expression of inflammation-and efferocytosisrelated molecule expression within the plaque by immunohistochemical analysis. We found that anti-Gas6 staining was significantly lower in the plaques of cART group ( Figure VIC 
Overexpression of p90RSK in Myeloid Cells Accelerates Atherosclerosis
Previously, we reported that the overexpression of wildtype p90RSK inhibits ERK5 transcriptional activity via ERK5 S496 phosphorylation in endothelial cells, 14 and in the present study, we also obtained the same results using macrophages ( Figure IIIA in the online-only Data Supplement). We generated mice that specifically overexpressed wild-type p90RSK (WT-p90RSK; LysMCre
fl ], 32 referred to as [WT-p90rsk-MTg]) in myeloid cells. WT-p90rsk-MTg mice showed a roughly 2-to 3-fold increase in WT-p90RSK protein expression and ERK5 S496 phosphorylation (a marker of p90RSK activity) in peritoneal macrophages compared with their wild-type counterparts, including NLC mice ( Figure 5A ). Complete blood cell counts were obtained, which were comparable in NLC and WT-p90rsk-MTg mice (Figure 5B) . The mRNA expression levels of efferocytosis-related genes, as well as an M2-type macrophage marker, Arg1, were significantly lower in cells isolated from WTp90rsk-MTg mice ( Figure 5C ). In contrast, annexin V expression in peritoneal macrophages was not affected (Figure VIH in the online-only Data Supplement).
To determine the role of the macrophage p90RSK in the development of atherosclerosis, we bred NLC and WT-p90rsk-MTg mice into the Ldlr −/− background and fed them a high-fat diet for 12 weeks and 16 weeks, respectively. No differences were noted in their body weight or their low-density lipoprotein and high-density lipoprotein cholesterol levels ( Figure VIIA and VIIB in the online-only Data Supplement). However, the atherosclerotic lesion area observed in the en face sample of the aorta was significantly larger in WT-p90rsk-MTg/Ldlr −/− mice than in NLC/Ldlr −/− mice ( Figure 6A and 6C [left] and 6F and 6G). Larger lesions were also found in histological cross-sections at the aortic valve area in WT-p90rsk-MTg/Ldlr −/− mice than in NLC/Ldlr −/− mice ( Figure 6B and 6C [right] and 6H and 6I). Plaque necrosis is the consequence of apoptotic cell accumulation in advanced lesions. 30 Therefore, we assessed the effect of p90RSK overexpression on apoptotic cell accumulation. The number of TUNEL-positive nuclei was significantly higher in WT-p90rsk-MTg/Ldlr −/− mouse lesions with larger necrotic cores than in NLC/Ldlr −/− mouse lesions ( Figure 6D, 6E, and 6J) . Because annexin V expression in peritoneal macrophages was unaffected by p90RSK overexpression ( Figure VIH in the online-only Data Supplement), it is possible that the apoptotic cell accumulation observed in WT-p90rsk-MTg/Ldlr −/− mouse lesions was not caused by increased apoptosis but by defective clearance of apoptotic cells or efferocytosis.
To further establish the role of myeloid cell-specific p90RSK in atherosclerosis, we generated myeloid cellspecific, dominant-negative p90RSK transgenic (LysM-
To verify the expected dominant negativeness of this model animal, we created BMDMs from DN-p90rsk-MTg and control NLC mice; stimulated them with cART, TNFα, or vehicle for 30 minutes; and assayed them for ERK5 S496 phosphorylation, a marker for p90RSK activity. We found that the increase in ERK5 S496 phosphorylation because of cART or TNFα treatment was lost in cells isolated from DN-p90rsk-MTg mice ( Figure 7A through 7D), establishing that macrophages from DN-p90rsk-MTg mice have little to no p90RSK activity. Complete blood cell counts were obtained, which were comparable in NLC and DN animals ( Figure VIIC in the onlineonly Data Supplement). When BMDMs from NLC mice were exposed to cART or TNFα, ARE reporter luciferase activity was blocked. In contrast, this inhibition was not detected in BMDMs from DN-p90rsk-MTg mice (Figure 7E and 7F) . We also found that cART and TNFα treatment led to reduced protein expression of Gas6, heme oxygenase 1, and thioredoxin 1 and accumulation of TNFα (only by cART), p16, and p21 in cells from NLC mice. These effects, however, were not seen in BMDMs from DN-p90rsk-MTg mice ( Figure 7G ORIGINAL RESEARCH ARTICLE within 10 minutes after incubation, which was significantly attenuated in BMDMs from DN-p90rsk-MTg mice ( Figure 7I and 7J) . These data lend support to the theory that p90RSK is a key player in regulating efferocytosis, inflammation, antioxidant expression, and senescence via mitochondrial ROS production.
Next, to determine whether specific activation of p90RSK in macrophages is involved in atherogenesis, we used PCL models of NLC (wild-type C57Bl/6) and DN-p90rsk-MTg mice injected with rAAV8-expressing mouse gain-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutant of D377Y-PCSK9 (rAAV8-mD377Y-PCSK9). 31 It is interesting to note that the severity of obesity induced by a high-fat diet after this injection was significantly lower in DN-p90rsk-MTg mice than in wild-type mice ( Figure IXA in the onlineonly Data Supplement). However, there was no notable difference in cholesterol levels among these mice 56 days after rAAV8-mD377Y-PCSK9 injection and 28 days after partial ligation ( Figure IXB in the online-only Data Supplement). Previously, we reported a significant increase in macrophage infiltration into the plaque after PCL in mice with hypercholesteremia, which distinguishes these plaques from the restenosis lesions seen during vascular intimal formation after vascular injury. 32 When we isolated the carotids, we first examined the ratio of the area of the plaque lesion and total left coronary artery area as the gross lesion (%) as described in , 10 µmol/L each; A) or tumor necrosis factor α (TNFα; 20 ng/mL; C) for 0 to 30 min, and p90RSK activation (S380 phosphorylation), ERK5 S496 phosphorylation, ERK5 TEY motif phosphorylation, and total p90RSK and ERK5 expression were detected by Western blotting using specific antibodies, as indicated. B and D, The graph represents the densitometry data of immunoblots (n=3), similar to those shown in A and C. The data are the means±SD. **P<0.01; *P<0.05. E and F, BMDMs from NLC and DN-p90rsk-MTg mice were transfected with the ARE luciferase reporter and the constitutively expressing Renilla luciferase vector for 16 h. Cells were incubated with (E) cART (TDF/FTC/ATV/RTV, 10 µmol/L each) or (F) TNFα (20 ng/mL) for 6 h, and NRF2-ARE transcriptional activity from 3 independent experiments was measured as described in the Methods. Mean±SD. **P<0.01. G and H, BMDMs from NLC and DN-p90rsk-MTg mice were incubated with cART (TDF/FTC/ATV/RTV, 10 µmol/L each) or TNFα (20 ng/mL) for 24 h. Western blotting was performed using antibodies against the indicated proteins. I and J, BMDMs from NLC and DN-p90rsk-MTg mice were incubated with cART (TDF/FTC/ATV/RTV, 10 µmol/L each; I) or TNFα (20 ng/mL; J) for 0 (−) or (+) 10 min and then treated with MitoSOX Red for 10 min, and mitochondrial ROS levels were detected as described in the Methods. Mean±SD (n=3). **P<0.01. ARE indicates antioxidant responsive element; ERK5, extracellular signal regulated kinase 5; GPx1, Glutathione peroxidase 1; HO1, Heme oxygenase 1; P90RSK, p90 ribosomal s6 kinase; ROS, reactive oxygen species; TEY: Thr-Glu-Tyr motif; and Trx1, Thioredoxin 1.
ORIGINAL RESEARCH ARTICLE
the Methods and found that the gross lesion was much smaller in the DN-p90rsk-MTg mice group than in the NLC group ( Figure 8A and 8B) . Next, we made serial sections through the entire carotid arteries, and the ratio of left coronary artery total area (intima + media) and right coronary artery wall area was calculated as described 32 E, Necrotic core formation was quantified by a grading system, as described in Methods. Mean±SD (n=10-13). **P<0.01. F, The scheme depicts the mechanisms and roles of p90RSK activation in combination antiretroviral therapy (cART)/tumor necrosis factor α (TNFα)-induced atherosclerotic plaque formation. cART and TNFα activate p90RSK by inducing mitochondrial reactive oxygen species (ROS) production within 30 min after stimulation (acute phase) and subsequently promote ERK5 S496 phosphorylation and downregulate NRF2-ARE transcriptional activity without affecting NRF2 and CD36 expression levels. This downregulation of NRF2-ARE transcriptional activity leads to the upregulation of (1) inflammation and (2) the expression of senescence-related molecules and the downregulation of (3) efferocytosis and (4) antioxidant-related molecule expression. After 24 h of cART and TNFα stimulation of macrophages (chronic phase), monocytes and macrophages are sensitized to the secondary insult of ROS; this is completely lost after treatment with NRF2 activator, suggesting that the reduction in NRF2-ARE transcriptional activity, in particular antioxidants and telomere shortening, contributes to cART/TNFα-mediated priming of monocytes and macrophages to a secondary insult by ROS. ERK5 indicates extracellular signal regulated kinase 5; LCA; left coronary artery; NRF2-ARE, MF-E2 related factor 2-antioxidant responsive element; P90RSK, p90 ribosomal s6 kinase; and RCA, right coronary artery. Figure 8C and 8D). Last, we determined necrotic core formation as described in the Methods and found a clear necrotic core (noncellular area) formation in the plaques of the NLC group, but a less developed necrotic core formation in those of the DN-p90rsk-MTg mice group ( Figure 8E) .
To determine the effect of cART only, we treated DNp90rsk-MTg and NLC mice (fed a normal chow diet) with cART twice (20 hours and then 4 hours before euthanasia) and measured VCAM-1 expression in endothelial cells in the atheroresistant greater curvature area of the aortic arch. We found a significant increase in VCAM-1 expression in the NLC mice, but such an increased VCAM-1 expression was not observed in DNp90rsk-MTg mice ( Figure IXC and IXD in the online-only Data Supplement).
DISCUSSION
The use of cART has changed the natural history of HIV infection, allowing patients to live longer. However, this benefit comes at the cost of an increased risk of HIV-associated comorbidities, such as CVD. Indeed, several large retrospective studies have shown an increased incidence of myocardial infarction. [33] [34] [35] HIV-associated CVD is likely the result of multiple interactions, including traditional CVD risk factors, HIV viral proteins, chronic immune activation, and the effects of antiretroviral therapy. Particular attention has been paid to the metabolic abnormalities seen in HIV + patients on long-term cART. These metabolic changes include insulin resistance and an atherogenic lipid profile that is characterized by elevated low-density lipoprotein cholesterol and triglyceride levels, as well as decreased high-density lipoprotein cholesterol levels. 36 Some of these metabolic changes have been related to cART-induced mitochondrial dysfunction. 37 However, how the key events in atherogenesis that lead to CVD are affected by cART in HIV + individuals is not well known. In this study, we focused on monocytes because they play a central role in atherogenesis by entering the intima and differentiating to macrophages under proinflammatory conditions, thereby actively participating in plaque formation. 38 We have provided compelling evidence that cART initiates a cycle of p90RSK activation/sensitization via increasing the production of mitochondrial ROS in monocytes/macrophages. p90RSK activation because of elevated oxidative stress causes phosphorylation of ERK5 at S496 residue, in turn decreasing NRF2-ARE transcriptional activity. These signaling pathways sensitize monocytes/macrophages to ROS and accelerate atherosclerosis via inducing the senescent phenotype by reducing monocyte/macrophage efferocytosis activity, reducing antioxidant molecules expression and telomere lengths, and increasing monocyte/macrophage inflammatory phenotypes ( Figure 8F) .
The clinical importance of p90RSK activation in monocytes was confirmed by the observation that monocytes from HIV-infected, cART-treated individuals were more sensitive to oxidative stress (increased levels of p90RSK enzymatic activity) than were those from noninfected, nontreated individuals. It is interesting to note that the results of multivariate logistic regression analyses indicate that this increased sensitivity of monocytes is not associated with a specific cART regimen or active HIV replication (as measured by detectable viral load) and is not correlated with Reynolds cardiovascular risk score. These findings highlight the role of cART broadly (not limited to 1 specific regimen) in modulating the p90RSK-ERK5 axis, rather than HIV infection, in a manner that is independent of conventional CVD risk factors. Furthermore, basal levels of p90RSK were found to be correlated with plaque formation as detected by sonography. Similar results were obtained in cART-treated Ldlr −/− mice, wherein the treatment accelerated atherosclerosis and resulted in a larger plaque size.
Although we did not detect a significant relationship between plaque formation and HIV status alone, we found a strong link between plaque formation and the combination of basal p90RSK activity and HIV status in a multivariate stepwise regression analysis. No significant relationship between plaque formation and the levels of H 2 O 2 -induced p90RSK activation was detected. However, we postulate that basal p90RSK activity in human peripheral monocytes represents the status of monocyte activation after the initial priming of the cells to mitochondrial ROS. Therefore, the basal level of p90RSK activity can demonstrate a stronger relationship to plaque formation than can p90RSK activity after H 2 O 2 treatment. A longitudinal follow-up of the patients is underway that will provide more conclusive results.
A recent report by Beckman et al 39 showed that HIV infection is associated with a 19% increase over the risk of peripheral arterial disease beyond that which can be attributed to traditional CVD risk factors. However, this increase was found only in individuals with CD4 counts <200 cells/µL. Although their study and ours focus on CVD on HIV + patients, there are important differences between the 2 studies, including the clinical end point, the cohort composition, and the prospective data acquisition. In our study, the mean CD4 cell count was 754.24/µL, and HIV replication was well controlled. Although Beckman et al 39 reported that HIV + military veterans with time-updated (current) CD4 cell counts >500 cells/µL had no increased risk of peripheral arterial disease, 39 but we found that the combination of basal p90RSK activation and HIV status was significantly correlated with carotid plaque formation, which was predictive of future cardiovascular events. In addition, the mean age of HIV + patients was 55.68 years in our study
ORIGINAL RESEARCH ARTICLE
versus 48.0 years in the other study. 39 Because the HIV prevalence rate among people >50 years of age has been steadily increased, 40 our data on older participants are representative of this population, which is at higher risk for CVD, independently of CD4 cell counts.
In vitro experiments using human and mouse monocytes/macrophages further delineated the mechanisms that underlie cART-mediated sensitization of monocytes/macrophages to ROS via provoking the senescent phenotype. We found that cART decreased the expression of antioxidants and telomere length via stimulating p90RSK and consequently inhibiting NRF2-ARE transcriptional activity. ERK5 has been shown to upregulate NRF2 transcriptional activity, and it is plausible that the reduction in ERK5 transcriptional activity induced by p90RSK leads to the inhibition of NRF2-ARE transcriptional activity and subsequent antioxidant expression. The protective role of telomere against oxidative stress has been well established, 41, 42 and cART was found to significantly shorten telomeres in monocytes/ macrophages, thus further sensitizing these cells to oxidative stress. Therefore, p90RSK-NRF2 activation can coordinately regulate various aspects of the senescent phenotype, in that p90RSK activation sensitizes its own activation in response to ROS by inducing the senescent phenotype, which results in reduced antioxidant expression and short telomere length.
Because p90RSK is activated by mitochondrial ROS, 22, 43 we investigated the effect of cART on mitochondrial ROS activity and its potential link with p90RSK activation in monocytes. Along similar lines, various studies have investigated the effect of different cART drugs on mitochondrial function. 34, 35, 44 It is important to emphasize that cART and many other drugs can target mitochondria by accumulating in the matrix or the inner mitochondrial membrane, both of which possess the unique physicochemical characteristics of the mitochondrial matrix. 17 Therefore, lipophilic compounds of cationic character and weak acids in anionic forms can accumulate in mitochondria and produce ROS and reactive nitrogen species by interfering with the mitochondrial respiratory chain. 45 In accordance with these reports, our results indicate that cART-induced mitochondrial ROS plays a crucial role in the subsequent activation of p90RSK in monocytes/macrophages.
To more conclusively establish the key role of p90RSK in atherosclerosis, we used mouse models with both gainand loss-of-function (myeloid cell-specific overexpression of WT or DN-p90RSK). We did not find any differences in the lipid profile among the different groups of mice examined. This is particularly relevant because integrase inhibitors, which are a recent addition to the groups of cART drugs, are associated with favorable lipid profiles. For this reason, it has been suggested that integrase inhibitors would be preferred drug candidates in patients with elevated cardiovascular risk. 46 ,47 However, we found that elvitegravir, 1 of the 2 integrase inhibitors we tested, significantly increased p90RSK activity and subsequent ERK5 S496 phosphorylation in in vitro experiments. In addition, p90RSK activation in macrophages promoted atherosclerosis without affecting the lipid profile in our mouse models. Hence, it is important to further investigate the effect of integrase inhibitors as the drugs of choice for HIV + individuals with a high risk for CVD.
Conclusions
In summary, our findings demonstrate that peripheral monocyte p90RSK activity can be a biomarker for cARTinduced CVD events. Because the p90RSK-NRF2 signaling pathway in myeloid cells regulates multiple cellular processes, which concurrently induce the senescent phenotype, upregulate inflammation and oxidative stress response, and downregulate telomere length and efferocytosis, this pathway can be targeted to develop therapeutic strategies for reducing cART-induced atherosclerosis and possibly other causes of CVD depending on p90RSK activation. One of the limitations of this study was the cross-sectional analysis of the clinical data. Longitudinal data are being collected and will become available in the next few years. However, the data already reported, combined with the in vitro, animal, and human data, strongly suggest that p90RSK activation in myeloid cells is critical in atherogenesis and provides a common pathway for several antiretroviral drugs to contribute to atherosclerosis. Please refer to Figures X and XI in the online-only Data Supplement for further information on the repeatability of p90RSK activity measurements described in the online-only Data Supplement and supplementary discussion on Glagov's effect, respectively. Also please refer to Tables V and VI in the online-only Data Supplement for further information on the real-time PCR described in the online-only Data Supplement and the supplemental discussion on viremia, plaque, and p90RSK activity in our clinical study, respectively.
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